Soligenix Inc. (0A6I)
LSE 
Summary
0A6I Chart
Soligenix to Present at November 21st Virtual Investor Summit Microcap Event
PRINCETON, NJ / ACCESSWIRE / November 15, 2024 / Soligenix, Inc. (Nasdaq:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting at the upcoming Q4 Investor Summit and will be available for 1-on-1 meetings throughout the day. Event: Q4 Investor Summit Presentation Time: 12:00pm - 12:30pm ET Location: Click Here The theme is 40 micro-cap companies with a catalyst and/or strong performance in the current market.
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
Princeton, NJ, October 24, 2024 – PRISM MediaWire – Soligenix, Inc.
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / August 16, 2024 / RedChip Companies will air interviews with Soligenix Inc. (Nasdaq:SNGX) and American Resources Corp. (Nasdaq:AREC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 17, at 7 p.m. Eastern Time (ET).
Soligenix Inc. (0A6I) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Soligenix Inc. ever had a stock split?
Soligenix Inc. Profile
| Biotechnology Industry | Healthcare Sector | Christopher J. Schaber CEO | LSE Exchange | US8342236044 ISIN |
| US Country | 14 Employees | - Last Dividend | 1 Feb 2012 Last Split | 15 Jun 1987 IPO Date |
Overview
Soligenix, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing products to treat rare diseases within the United States. The company diversifies its endeavors across two core segments: Specialized BioTherapeutics and Public Health Solutions. Originally founded as DOR BioPharma, Inc., Soligenix underwent a rebranding in 2009 to more accurately reflect its evolved focus and extensive expertise in the biotherapeutic and public health sectors. Since its establishment in 1987, Soligenix has endeavored to address unmet medical needs through innovative treatments, underpinned by a commitment to improving patient outcomes in rare diseases. The company's headquarters are situated in Princeton, New Jersey, positioning it within a hub of pharmaceutical innovation and development.
Products and Services
Soligenix, Inc. has meticulously developed a diverse portfolio of product candidates and services across its two operational segments:
- SGX301 (HyBryte): A novel photodynamic therapy that has successfully completed Phase III clinical trials for the treatment of cutaneous T-cell lymphoma. This innovative treatment represents a significant advancement in addressing a debilitating and rare skin cancer.
- SGX942: Developed within the umbrella of innate defense regulator (IDR) technology, SGX942 is in Phase III clinical trials aimed at the treatment of oral mucositis in head and neck cancer. This product underscores Soligenix's commitment to addressing inflammatory diseases with significant unmet medical needs.
- SGX302: Another promising candidate harnessing IDR technology, SGX302, is in a Phase IIa study to treat mild-to-moderate Psoriasis, indicating Soligenix's dedication to expanding its therapeutic solutions across various dermatological conditions.
- SGX945 and IDR technology: In Phase IIa protocol, this treatment is designed for the management of Aphthous Ulcers in Behçet's Disease, diversifying the company's portfolio into oral health and further affirming its focus on rare disease therapeutics.
- RiVax: As part of the Public Health Solutions segment, RiVax is a ricin toxin vaccine candidate which has completed Phase Ia, Ib, and Ic clinical trials, showcasing Soligenix's commitment to combating biothreats through innovative vaccine development.
- SGX943: A therapeutic candidate in the pre-clinical stage, aimed at the treatment of antibiotic-resistant and emerging infectious diseases, highlighting the company’s forward-thinking approach in addressing global health challenges.
- ThermoVax: A technology in pre-clinical development designed for thermostabilizing vaccines, which promises to enhance the storage and distribution of vaccines, especially in regions with limited access to cold chain logistics.
- CiVax: This vaccine candidate for the prevention of COVID-19 represents Soligenix's timely response to the global pandemic, reflecting its agility and commitment to public health preparedness and response.
